Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Rivaroxaban Reduces Recurrence of Symptomatic VTE: Bayer
January 18, 2010
- Proposed GLs for Oral Hypoglycemic Agents Require Long-Term Studies on All Two-Drug Combinations
January 18, 2010
- Novartis Obtains Diovan's Successor by Acquiring Corthera
January 18, 2010
- KRAS Gene Test Conducted in Only 12% of Patients
January 18, 2010
- Prof. Yamanaka Shows Great Hope for CP-690550 as 4th-Generation Immunosuppressant
January 18, 2010
- AnGes Terminates Cross Licensing Agreement for NF-кB
January 18, 2010
- Fall in the Number of OB/GYN Doctors Halted: Korosho
January 18, 2010
- 1st Product Using Elan's DDS Technology Approved in Japan
January 18, 2010
- Transplacental Administration of Antiarrhythmic Agents Given Conditional Approval
January 18, 2010
- Hatoyama Administration's 1st Budget Proposal for FY2010 Approved by Cabinet
January 18, 2010
- JMA Opposed to Any Decrease in Repeat Consultation Fee Clinics
January 18, 2010
- New Growth Strategy to Focus on Health, Environment, Tourism
January 18, 2010
- 3 Novartis A (H1N1) 2009 Flu Vaccines Prequalified by WHO
January 18, 2010
- DSP Applies for Lurasidone in the US
January 18, 2010
- ON THE MOVE
January 18, 2010
- Teijin Pharma Applies for TMX-67 in Japan
January 18, 2010
- Common Approval System Needed in Asia: Mr Shoda
January 18, 2010
- Herceptin Receives Positive Opinion for Advanced Stomach Cancer from CHMP
January 18, 2010
- Top Management Stresses Need to Develop New Products in New Year's Speeches
January 18, 2010
- Industry Must Make Further Investment in R&D to Introduce Better Pricing System
January 18, 2010
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…